Galcanezumab for the prevention of migraine

被引：4
作者：
Frerichs, Lindsay M. [1 ,2 ]
Friedman, Deborah, I [1 ,3 ]
机构：
[1] Univ Texas Southwestern Med Ctr Dallas, Dept Neurol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA
[2] Washington Univ, Dept Neurol, Sch Med St Louis, 660 S Euclid Ave, St Louis, MO 63110 USA
[3] Univ Texas Southwestern Med Ctr Dallas, Dept Ophthalmol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA
来源：
PAIN MANAGEMENT | 2021年 / 11卷 / 02期
关键词：
CGRP monoclonal antibody; galcanezumab; headache; migraine; prevention; treatment; GENE-RELATED PEPTIDE; EPISODIC MIGRAINE; DOUBLE-BLIND; MONOCLONAL-ANTIBODY; HEADACHE; PLACEBO; SAFETY; EFFICACY; CGRP; PHARMACOKINETICS;
D O I：
10.2217/pmt-2020-0030
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Migraine is a common and disabling disorder affecting approximately 1.02 billion people worldwide. Calcitonin gene-related peptide (CGRP) has been identified as playing an important role in the pathophysiology of migraine and several migraine-specific therapies targeting the CGRP ligand or its receptor have been approved since 2018 for the acute and preventive treatment of migraine. This review focuses on the pharmacology, clinical efficacy and safety/tolerability of galcanezumab, an anti-CGRP monoclonal antibody approved for the prevention of migraine.
引用
收藏
页码：101 / 112
页数：12
相关论文
共 60 条
  • [1] Positive response to galcanezumab following treatment failure to onabotulinumtoxinA in patients with migraine: post hoc analyses of three randomized double-blind studies
    Ailani, J.
    Pearlman, E.
    Zhang, Q.
    Nagy, A. J.
    Schuh, K.
    Aurora, S. K.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 (03) : 542 - 549
  • [2] Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies
    Bangs, Mark E.
    Kudrow, David
    Wang, Shufang
    Oakes, Tina M.
    Terwindt, Gisela M.
    Magis, Delphine
    Yunes-Medina, Laura
    Stauffer, Virginia L.
    [J]. BMC NEUROLOGY, 2020, 20 (01)
  • [3] Adherence with Migraine Prophylaxis in Clinical Practice
    Berger, Ariel
    Bloudek, Lisa M.
    Varon, Sepideh F.
    Oster, Gerry
    [J]. PAIN PRACTICE, 2012, 12 (07) : 541 - 549
  • [4] Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study
    Bigal, Marcelo E.
    Dodick, David W.
    Rapoport, Alan M.
    Silberstein, Stephen D.
    Ma, Yuju
    Yang, Ronghua
    Loupe, Pippa S.
    Burstein, Rami
    Newman, Lawrence C.
    Lipton, Richard B.
    [J]. LANCET NEUROLOGY, 2015, 14 (11) : 1081 - 1090
  • [5] Patterns of Use and Reasons for Discontinuation of Prophylactic Medications for Episodic Migraine and Chronic Migraine: Results From the Second International Burden of Migraine Study (IBMS-II)
    Blumenfeld, Andrew M.
    Bloudek, Lisa M.
    Becker, Werner J.
    Buse, Dawn C.
    Varon, Sepideh F.
    Maglinte, Gregory A.
    Wilcox, Teresa K.
    Kawata, Ariane K.
    Lipton, Richard B.
    [J]. HEADACHE, 2013, 53 (04): : 644 - 655
  • [6] Migraine Epidemiology, Burden, and Comorbidity
    Burch, Rebecca C.
    Buse, Dawn C.
    Lipton, Richard B.
    [J]. NEUROLOGIC CLINICS, 2019, 37 (04) : 631 - +
  • [7] Migraine: Multiple Processes, Complex Pathophysiology
    Burstein, Rami
    Noseda, Rodrigo
    Borsook, David
    [J]. JOURNAL OF NEUROSCIENCE, 2015, 35 (17) : 6619 - 6629
  • [8] Targeting calcitonin gene-related peptide: a new era in migraine therapy
    Charles, Andrew
    Pozo-Rosich, Patricia
    [J]. LANCET, 2019, 394 (10210) : 1765 - 1774
  • [9] Detke H, 2019, NEUROLOGY, V92
  • [10] Galcanezumab in chronic migraine The randomized, double-blind, placebo-controlled REGAIN study
    Detke, Holland C.
    Goadsby, Peter J.
    Wang, Shufang
    Friedman, Deborah I.
    Selzler, Katherine J.
    Aurora, Sheena K.
    [J]. NEUROLOGY, 2018, 91 (24) : E2211 - E2221
123456